A dry powder medecine inhaler has an impeller (31) non-concentrically disposed in a mixing chamber (25). A motor spins the impeller at high speed. A plunger (106) introduces a dose of powdered medecine into the chamber so that all powder particles are available for intermixing disaggregation and comminution. An aperture (51) receives a first stream of air and passes it towards the mouthpiece for inhalation by the user. A wall (11) has at least one aperture (59) for diverting a portion of a main air stream into the aerosolizing chamber to mix with the particles to form a fine, low density, low velocity, dry mist of powdered medecine for inhalation by the user.

Dry powder inhaler

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Dry powder inhaler and system for drug delivery

Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.

Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent

Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.

Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents

Described herein are interactive apparatus and methods for sensing and measuring real-time characteristic patterns of a subject's use of a dry powder inhalation system. The devices can be used in a wired or wireless communication mode to communicate with a display to assess the subject's usage of the inhalation system, to evaluate the performance of the inhalation system and/or to detect the characteristics profile of a dry powder formulation emitted from the inhalation system in use.

Interactive apparatus and method for real-time profiling of inhalation efforts

Dry powder blister packages include sealed blisters that incorporate or cooperate with a piezoelectric active layer that flexes to vibrate the dry powder in a blister to facilitate active dispersion.

Jeffrey A. Warden

Papers

Blister packages and associated methods of fabricating dry powder drug containment systems